Drug Trial Radar · NCT03495882
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Dec 18, 2017
Primary completion
Jul 15, 2022
Study completion Jul 15, 2022
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label study of zalifrelimab (AGEN1884) in combination with balstilimab (AGEN2034) in participants with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer. Balstilimab is a novel, fully human monoclonal immunoglobulin G4 antibody, designed to block program cell death-1 (PD-1). Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1 antibody, designed to block cytotoxic T-lymphocyte antigen-4 (CTLA-4).
Conditions
- Cervical Cancer
Interventions
ZalifrelimabDrug
Zalifrelimab was administered over 30 minutes and following the infusion of balstilimab.
BalstilimabDrug
Balstilimab infusion was administered over 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Objective Response Rate (ORR) - Independent Endpoint Review Committee (IERC)Time frame: Up to 2 years
- Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: First 21 days of treatment
Locations
47 sites in 9 countries. Site status is shown where the registry gives one.
Comprehensive Care and Research Center
Goodyear, Arizona
City of Hope National Medical Center
Duarte, California
University of Miami
Miami, Florida
BRCR Medical Center, Inc
Plantation, Florida
Augusta University
Augusta, Georgia
Cancer Treatment Centers of America
Zion, Illinois
Ochsner Cancer Institute
New Orleans, Louisiana
West Michigan Cancer Center
Kalamazoo, Michigan
University of Oklahoma
Oklahoma City, Oklahoma
Chattanooga's Program In Women's Oncology
Chattanooga, Tennessee
CliniCore International
Baytown, Texas
Providence Regional Cancer System
Aberdeen, Washington
Swedish Cancer Institute
Seattle, Washington
Mater Research
South Brisbane, Australia
Icon Cancer Care South Brisbane
South Brisbane, Australia
Scientia Clinical Research
Sydney, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda.
São Paulo, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer
São Paulo, Brazil
LLC Arensia Exploratory Medicine
Tbilisi, Georgia
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, Hungary
Orszagos Onkologiai Intezet
Budapest, Hungary
Debreceni Egyetem
Debrecen, Hungary
Bacs-Kiskun Megyei Korhaz
Kecskemét, Hungary
Pecsi Tudomanyegyetem
Pécs, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
Szolnok, Hungary
Zala Megyei Szent Rafael Korhaz
Zalaegerszeg, Hungary
ARENSIA Exploratory Medicine Unit, Institute of Oncology
Chisinau, Moldova
BioResearch Group SP. Z O.O.
Nadarzyn, Poland
Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
Warsaw, Poland
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
START Madrid. Oncology Phase I
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU
Dnipro, Ukraine
CI Transcarpathian Cl Onc Center Dep of Surgery #1 SHEI Ivano-Frankivsk NMU
Ivano-Frankivsk, Ukraine
Communal Non-profit Enterprise Regional Center of Oncology
Kharkiv, Ukraine
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.